HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

72.300

+0.3500.49%

Volume:1.44M

Turnover:103.17M

Market Cap:14.39B

PE:-51.23

High:73.850

Open:73.850

Low:69.750

Close:71.950

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:0.97

T/O Rate:0.73%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.411

ROE:-27.61%

ROA:-9.92%

PB:9.75

PE(LYR):-51.23

PS:69.60

Loading ...

Overview Company News Filings

Movement Alert｜LEADS BIOLABS-B Rises 5.18% in Regular Trading, Dense Pipeline Catalysts Continue to Drive Momentum

Movement Alert｜LEADS BIOLABS-B Rises 5.06% in Regular Trading, Multiple Pipeline Catalysts Drive Positive Sentiment

Nanjing Leads Biolabs Jumps on Progress of Tumor Antibody Treatment

Movement Alert｜LEADS BIOLABS-B Rises 5.34% in Regular Trading, Phase II HCC Study Advances to Expansion Stage

Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals

THOMSON REUTERS

Nanjing Leads Biolabs Says Phase II Opamtistomig Trial in First-Line Liver Cancer Enters Expansion Phase

Leads Biolabs: Phase II Opamtistomig Trial for First-Line Liver Cancer Enters Expansion Stage

Bulletin Express

LEADS BIOLABS-B Advances Phase II Study of Vilitis™ in Hepatocellular Carcinoma to Expansion Stage

Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of Lbl‑051 for Refractory Autoimmune Diseases

THOMSON REUTERS

Leads Biolabs’ partner Oblenio opens Phase Ia trial for trispecific T-cell engager LBL-051; company clarifies connected share-award transaction

Bulletin Express

Nanjing Leads Biolabs Clarifies Award Grant to Executive Director is Exempt Connected Transaction Under HK Rules

Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Ind Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

THOMSON REUTERS

LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment

LEADS BIOLABS-B Shares Shift with HK$364 Million in Custody Transfers, Representing 3.62% of Total

Nanjing Leads Biolabs Co - Lbl-024 Receives Ind Approval from Nmpa for Metastatic Colorectal Cancer

THOMSON REUTERS

Nanjing Leads Biolabs Says China Regulator Clears IND for Lbl-024 in Metastatic Colorectal Cancer

Movement Alert｜LEADS BIOLABS-B Rises 5.11% in Regular Trading, Core Pipeline Cholangiocarcinoma Phase II Study Completes Full Patient Enrollment

LEADS BIOLABS-B (09887) Records 346 Million Hong Kong Dollar Share Transfer, Representing 3.39% of Total Shares

Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Completes Patient Enrollment in Phase Ii Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors

THOMSON REUTERS

Leads Biolabs completes full enrollment of 70-patient Phase II trial for bispecific antibody LBL-024 in first-line advanced biliary tract cancer

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/09887/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":72.3,"timestamp":1788163728010,"preClose":71.95,"halted":0,"volume":1444087,"delay":0,"changeRate":0.004864489228630914,"floatShares":198000000,"shares":199000000,"eps":-1.411208261482991,"marketStatus":"Closed","change":0.35,"latestTime":"08-31 16:08:48","open":73.85,"high":73.85,"low":69.75,"amount":103174580,"amplitude":0.056984,"askPrice":72.3,"askSize":36900,"bidPrice":72.25,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.372720763442546,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":71.95,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.974167,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.411208,"volumeRatio":0.974167,"shares":199000000,"dividePrice":0,"high":73.85,"amplitude":0.056984,"preClose":71.95,"low":69.75,"week52Low":44.72,"pbRate":"9.75","psRate":"69.60","week52High":97.5,"institutionHeld":0,"latestPrice":72.3,"committee":-0.989218,"eps":-1.411208261482991,"divideRate":0,"volume":1444087,"delay":0,"ttmEps":-1.372720763442546,"open":73.85,"prevYearClose":51,"prevWeekClose":71.95,"prevMonthClose":53.4,"prevQuarterClose":49.32,"fiveDayClose":69.05,"twentyDayClose":56.95,"sixtyDayClose":56.85},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-08-28","current":-51.354985,"percent":0.130597,"low":-76.458084,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"high":-30.202688,"avg":-42.108117,"sd":9.834997,"marketCap":14310265010},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160},{"date":"2026-08-28","current":-49.214108,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"marketCap":14310265010}],"updateTime":1788157220937},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1114260368","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.18% in Regular Trading, Dense Pipeline Catalysts Continue to Drive Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1114260368","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114260368?lang=en_us&edition=fundamental","pubTime":"2026-08-17 09:55","pubTimestamp":1786931757,"startTime":"0","endTime":"0","summary":"On August 17, LEADS BIOLABS-B rose 5.18% in regular trading, trading at HK$76.95/share, with turnover of HK$64.37 million.The rise extends recent momentum fueled by a series of clinical milestones....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Rises as Dense Pipeline Catalysts Continue to Drive Momentum","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145060311","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.06% in Regular Trading, Multiple Pipeline Catalysts Drive Positive Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=1145060311","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145060311?lang=en_us&edition=fundamental","pubTime":"2026-08-14 14:24","pubTimestamp":1786688645,"startTime":"0","endTime":"0","summary":"On August 14, LEADS BIOLABS-B rose 5.06% in regular trading, trading at HK$72.3/share, with turnover of HK$119 million.The movement was driven by a cluster of recent positive developments. On August...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Rises, Multiple Pipeline Catalysts Drive Positive Sentiment","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657509468","title":"Nanjing Leads Biolabs Jumps on Progress of Tumor Antibody Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2657509468","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657509468?lang=en_us&edition=fundamental","pubTime":"2026-08-06 12:57","pubTimestamp":1785992261,"startTime":"0","endTime":"0","summary":"BUZZ-Nanjing Leads Biolabs jumps on progress of tumor antibody treatment** Shares of Nanjing Leads Biolabs9887.HKjump 8.3% to HK$62.85, the highest level since July 24** Stock of the China-based oncology therapies developer set for the biggest one-day pct gain since July 15** Company says Phase II clinical study evaluating its bispecific antibody PD-L1/4-1BB and Opamtistomig  for treatment of first-line hepatocellular carcinoma , or malignant tumor, has completed safety run in phase assessment review and has successfully entered expansion phase** Preliminary data show that Opamtistomig in combination with bevacizumab has demonstrated encouraging efficacy signals in patients with HCC with a favorable overall safety profile and good tolerability - co** YTD, stock up 23.1%, Hang Seng Biotech Index.HSBIOup 1.5%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N443044:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","09887","HK0000252160.HKD","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161568880","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.34% in Regular Trading, Phase II HCC Study Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1161568880","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161568880?lang=en_us&edition=fundamental","pubTime":"2026-08-06 10:55","pubTimestamp":1785984951,"startTime":"0","endTime":"0","summary":"On August 6, LEADS BIOLABS-B rose 5.34% in regular trading, trading at HK$60.9/share, with turnover of HK$75.61 million. The gain was driven by the company's announcement that its PD-L1/4-1BB...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657604570","title":"Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2657604570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657604570?lang=en_us&edition=fundamental","pubTime":"2026-08-06 08:53","pubTimestamp":1785977613,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUABKLW1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","HK0000500386.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572869","title":"Nanjing Leads Biolabs Says Phase II Opamtistomig Trial in First-Line Liver Cancer Enters Expansion Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572869","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572869?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:00","pubTimestamp":1785970810,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says Phase II Opamtistomig trial in first-line liver cancer enters expansion phaseNanjing Leads Biolabs reported its Phase II study of LBL-024 (opamtistomig) for first-line hepat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL4Rzf09:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131250364","title":"Leads Biolabs: Phase II Opamtistomig Trial for First-Line Liver Cancer Enters Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1131250364","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131250364?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:25","pubTimestamp":1785968734,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) reported that its self-developed PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has completed the safety run-in of a Phase II study in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193898777","title":"LEADS BIOLABS-B Advances Phase II Study of Vilitis™ in Hepatocellular Carcinoma to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1193898777","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193898777?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:20","pubTimestamp":1785968415,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that its independently developed PD-L1/4-1BB bispecific antibody, Opatsosumimab (Vilitis™), has successfully completed the safety run-in assessment in a Phase II...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","BK1161","09887","HK0000500386.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656055321","title":"Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of Lbl‑051 for Refractory Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2656055321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656055321?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:56","pubTimestamp":1785844585,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA5J5NW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252152.HKD","09887","HK0000500386.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152365137","title":"Leads Biolabs’ partner Oblenio opens Phase Ia trial for trispecific T-cell engager LBL-051; company clarifies connected share-award transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=1152365137","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152365137?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:24","pubTimestamp":1785842650,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that Oblenio Bio, its NewCo partner formed with Aditum Bio, has administered first doses to patients in a European Phase Ia, first-in-human...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656853074","title":"Nanjing Leads Biolabs Clarifies Award Grant to Executive Director is Exempt Connected Transaction Under HK Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2656853074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656853074?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:10","pubTimestamp":1785841828,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs clarifies award grant to executive director is exempt connected transaction under HK rulesNanjing Leads Biolabs issued a supplemental clarification on its July 1, 2026 award gran","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL1LdRlk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656342024","title":"Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Ind Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2656342024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656342024?lang=en_us&edition=fundamental","pubTime":"2026-08-03 11:43","pubTimestamp":1785728605,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA6LLSYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252152.HKD","BK1161","HK0000252160.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122893332","title":"LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1122893332","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122893332?lang=en_us&edition=fundamental","pubTime":"2026-08-03 10:32","pubTimestamp":1785724340,"startTime":"0","endTime":"0","summary":"Shares of LEADS BIOLABS-B (09887) rose nearly 6% in early trading, last up 5.71% at HK$56.45 with a turnover of HK$75.0476 million.On August 3, the company announced that China's National Medical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VXUS","BK1161","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK4585","KCAI","09887","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168072852","title":"LEADS BIOLABS-B Shares Shift with HK$364 Million in Custody Transfers, Representing 3.62% of Total","url":"https://stock-news.laohu8.com/highlight/detail?id=1168072852","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168072852?lang=en_us&edition=fundamental","pubTime":"2026-08-03 08:50","pubTimestamp":1785718227,"startTime":"0","endTime":"0","summary":"Data from the Hong Kong Stock Exchange shows that on July 31, LEADS BIOLABS-B (09887) experienced a notable change in share custody, with a total transfer value of HK$364 million, accounting for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","161027","09887","HK0000500386.USD","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656456073","title":"Nanjing Leads Biolabs Co - Lbl-024 Receives Ind Approval from Nmpa for Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656456073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656456073?lang=en_us&edition=fundamental","pubTime":"2026-08-03 06:05","pubTimestamp":1785708356,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260802:nFWN43Z00C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","BK1161","HK0000252152.HKD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656345985","title":"Nanjing Leads Biolabs Says China Regulator Clears IND for Lbl-024 in Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656345985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656345985?lang=en_us&edition=fundamental","pubTime":"2026-08-03 06:05","pubTimestamp":1785708354,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says China regulator clears IND for LBL-024 in metastatic colorectal cancerNanjing Leads Biolabs secured China NMPA clearance to start a new clinical trial of PD-L1/4-1BB bispeci","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260802:nNDL1zTHz6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252152.HKD","HK0000500386.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181232541","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.11% in Regular Trading, Core Pipeline Cholangiocarcinoma Phase II Study Completes Full Patient Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=1181232541","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181232541?lang=en_us&edition=fundamental","pubTime":"2026-07-31 10:03","pubTimestamp":1785463394,"startTime":"0","endTime":"0","summary":"On July 31, LEADS BIOLABS-B rose 5.11% in regular trading, trading at HK$52.9/share, with turnover of HK$37.318 million.On the news front, the company announced on July 30 that its core drug...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Leads Biolabs-B Rises; Core Cholangiocarcinoma Phase II Trial Fully Enrolled","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133179762","title":"LEADS BIOLABS-B (09887) Records 346 Million Hong Kong Dollar Share Transfer, Representing 3.39% of Total Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1133179762","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133179762?lang=en_us&edition=fundamental","pubTime":"2026-07-31 08:30","pubTimestamp":1785457819,"startTime":"0","endTime":"0","summary":" LEADS BIOLABS-B (09887) reported a significant change in its share position on July 30, with a total transfer value of 346 million Hong Kong dollars, accounting for 3.39% of its total shares.The...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","161027","09887","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655737958","title":"Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Completes Patient Enrollment in Phase Ii Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2655737958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655737958?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:36","pubTimestamp":1785407788,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA5JD7ZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157244498","title":"Leads Biolabs completes full enrollment of 70-patient Phase II trial for bispecific antibody LBL-024 in first-line advanced biliary tract cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1157244498","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157244498?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:28","pubTimestamp":1785407280,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has finalized patient recruitment for its Phase II clinical study of Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, in first-line treatment...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":139,"code":"91000000","status":"200"}]}}